目的 觀察吸入用布地奈德混懸液聯(lián)合注射用氫化可的松琥珀酸鈉治療小兒喘息性支氣管肺炎的臨床療效。方法 選取2015年2月-2017年3月南陽(yáng)市中心醫(yī)院收治的喘息性支氣管肺炎患兒70例為研究對(duì)象，采用隨機(jī)數(shù)表法將所有患兒分為對(duì)照組和治療組，每組各35例。對(duì)照組霧化吸入吸入用布地奈德混懸液，1 mg/次，2次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注注射用氫化可的松琥珀酸鈉，5~10 mg/kg，1次/d。兩組患兒均連續(xù)治療1周。觀察兩組的臨床療效，比較兩組的肺功能、血清炎癥因子和免疫球蛋白E（IgE）水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為77.14%、94.29%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組第一秒用力呼氣量（FEV1）、用力肺活量（FVC）、FEV1/FVC均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清腫瘤壞死因子（TNF-α）、白細(xì)胞介素-6（IL-6）、C-反應(yīng)蛋白（CRP）、IgE水平均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 吸入用布地奈德混懸液聯(lián)合注射用氫化可的松琥珀酸鈉治療小兒喘息性支氣管肺炎的療效較好，能明顯改善患兒肺功能，調(diào)節(jié)炎癥因子水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effects of Budesonide Suspension for inhalation combined with Hydrocortisone Sodium Succinate for injection in treatment of asthmatic bronchopneumonia in children. Methods Children (70 cases) with asthmatic bronchopneumonia in Nanyang Central Hospital from February 2015 to March 2017 were randomly divided into control and treatment groups, and each group had 35 cases. Children in the control group were aerosol inhalation administered with Budesonide Suspension for inhalation, 1 mg/time, twice daily. Children in the treatment group were iv administered with Hydrocortisone Sodium Succinate for injection on the basis of the control group, 5-10 mg/kg, once daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacies were evaluated, and lung function, serum inflammatory factors, and IgE levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.14% and 94.29%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-α, IL-6, CRP, and IgE in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Budesonide Suspension for inhalation combined with Hydrocortisone Sodium Succinate for injection has clinical curative effect in treatment of asthmatic bronchopneumonia in children, can significantly improve lung function, and regulate inflammatory factor levels, with good safety, which has a certain clinical application value.